Abstract 230: AZD4956, a potent and selective inhibitor of DNA polymerase theta, enhances the activity of DNA-damaging agents in HRR defective cellular backgrounds and improves efficacy of the new generation PARP1-selective inhibitor, saruparib.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: AstraZeneca (United Kingdom)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148869959
Cites:
Cited by:
Related to:
